News

A study found palliative care for dementia did not improve neuropsychiatric symptoms but reduced emergency visits and hospitalizations over 2 years.

Findings suggest the benefits of combined belatacept and tacrolimus immunosuppression after kidney transplantation for patient and all-cause graft survival.

Frevecitinib is a novel inhaled dry powder therapeutic in development for asthma that remains inadequately controlled by SOC inhaled maintenance therapies.

Results from the Phase 3 LIBerate-HoFH trial found LDL-C responses generally similar between patients treated with lerodalcibep and evolocumab.

In this analysis, investigators explored whether dietary sodium intake was linked with psoriasis and whether any subgroups of patients were more likely to report salt-sensitive psoriasis.

A trial found system- and community-based dementia care had no advantage over usual care, except for improved caregiver self-efficacy at 6 months.

Awarded to Roche, the Tina-quant® Lipoprotein (a) Gen.2 Molarity assay will be the first 510(k) cleared test measuring Lp(a) in nanomoles per liter (nmol/L).

Study findings suggest NMP is especially beneficial for DCD allografts and is linked to better outcomes and resource use than SCS.

These real-world, 52-week data demonstrate that deucravacitinib is effective for patients in various age brackets, though BMI has a slight impact on its efficacy.

Findings suggest MASLD, especially with diabetes, overweight, or hypertension, is associated with significant fibrosis in patients with HCV.

The study also revealed a predominant T2-low asthma endotype in majority Puerto Rican and Black or African American youth populations.

Only 7% of patients presenting to US emergency departments received cardiac biomarker testing, with 2.8% diagnosed with ACS.

These findings highlight dupilumab’s use as a potential treatment option for individuals with prurigo nodularis.

A study found penicillin allergy prevalence is higher in high-income countries (9.9%) than in middle-income ones (4.4%), highlighting disparities in reporting and research.

The FDA approved semaglutide to reduce the risk of kidney disease worsening, kidney failure, and death due to CVD in those with T2D and CKD.

Among multiple issues were confusing and conflicting misdiagnoses of asthma.

Patients who started dialysis as children but were not waitlisted until young adulthood faced worse outcomes than those who were listed before turning 18.

In this episode, Veeral Sheth, MD, is joined by the CEO of Orasis Pharmaceuticals to discuss Qlosi, a preservative-free, low-dose eye drop FDA-approved for presbyopia.

A new study found stimulant use in children dropped 19% early in the pandemic but rebounded, with the 2022 Adderall shortage prompting shifts to alternatives.

Compared with nonsurgical treatment, metabolic surgery was associated with reduced risks of incident MALO and progression to decompensation.

The findings in this analysis indicate that a balanced, infrequent diet including proteins and fats may provide individuals with a potential strategy for management of atopic dermatitis.

A study found no negative effect of food allergies on school performance, with better grades in severe cases, but results were nonsignificant in sibling analyses.

Results showed no difference in time to relapse, relapse rates, subsequent immunosuppression use, or kidney function between the medications.

The regulatory agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 14, 2025.

The FDA approved updated labeling for viloxazine ER capsules as an ADHD treatment, adding lactation data and details on serotonin 5-HT2C receptor activity.

Peter Kranke, MD, MBA, MME, and colleagues call for clarifications to the August 2024 recommendations with more real-world considerations.

Enobosarm led to a statistically significant benefit in the protection of lean mass in patients with overweight or obesity receiving semaglutide.